{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:12:59Z","timestamp":1762272779492,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.semerg.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:20:22Z","timestamp":1623111622000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efectividad y seguridad del tratamiento con iPCSK9 en vida real: experiencia de tres hospitales asturianos"],"prefix":"10.1016","volume":"47","author":[{"given":"R.","family":"Rodr\u00edguez Escobedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gonz\u00e1lez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"D\u00edaz Naya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Su\u00e1rez Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Fern\u00e1ndez Morera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Riestra Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mart\u00ednez Faedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Villaz\u00f3n Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.L.","family":"Men\u00e9ndez Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2021.03.008_bib0155","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2021.03.008_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2021.03.008_bib0165","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes\u20142020","volume":"43","year":"2020","journal-title":"Diabetes Care."},{"key":"10.1016\/j.semerg.2021.03.008_bib0170","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ."},{"key":"10.1016\/j.semerg.2021.03.008_bib0175","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.03.003","article-title":"NLA Task Force on Statin Safety \u2014 2014 update","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0180","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0185","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: Mechanism of action, efficacy, and safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev Cardiovasc Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: Current status, controversies, and future directions","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011748.pub2","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","author":"Schmidt","year":"2017","journal-title":"Cochrane Database of Systematic Reviews."},{"key":"10.1016\/j.semerg.2021.03.008_bib0200","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0205","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0210","unstructured":"Dictamen de la Comisi\u00f3n de Uso Racional de los Medicamentos y Productos Sanitarios (CURMP) sobre la inclusi\u00f3n en la gu\u00eda farmacoterap\u00e9utica del SESPA de Alirocumab y Evolocumab para el tratamiento de la hipercolesterolemia. Dictamen 09\/2017. Disponible en: https:\/\/www.astursalud.es\/documents\/31867\/36150\/INHIBIDORES+PCSK9+DICTAMEN+N%C3%82%C2%BA+9+2017.pdf\/2a5d9aca-aff8-f72f-b539-53e501c73f61"},{"key":"10.1016\/j.semerg.2021.03.008_bib0215","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2021.03.008_bib0225","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.semerg.2021.03.008_bib0230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.hjc.2019.10.003","article-title":"PCSK9 inhibitors in clinical practice: Novel directions and new experiences","volume":"61","author":"Rallidis","year":"2020","journal-title":"Hellenic J Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0235","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase2 study","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.semerg.2021.03.008_bib0240","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.semerg.2021.03.008_bib0245","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol\u2013lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label OSLER-1 extension study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0250","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0255","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0260","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: Pooled analysis of 1359 patients in four phase2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semerg.2021.03.008_bib0265","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0270","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2021.03.008_bib0275","article-title":"Safety and efficacy of alirocumab in a real-life setting: The ODYSSEY APPRISE study","author":"Gaudet","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0280","article-title":"Indirect comparison of the efficacy and safety of alirocumab and evolocumab: A systematic review and network meta-analysis","author":"Guedeney","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.semerg.2021.03.008_bib0285","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of evolocumab on vitaminE and steroid hormone levels: Results from the 52-week, phase3, double-blind, randomized, placebo-controlled DESCARTES study","volume":"117","author":"Blom","year":"2015","journal-title":"Circ Res."},{"key":"10.1016\/j.semerg.2021.03.008_bib0290","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"Cognition after lowering LDL-cholesterol with evolocumab","volume":"75","author":"Gencer","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0295","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","volume":"63","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semerg.2021.03.008_bib0300","first-page":"128","article-title":"Indicaciones de los inhibidores de PCSK9 en la pr\u00e1ctica cl\u00ednica. Recomendaciones de la Sociedad Espa\u00f1ola de Arteriosclerosis (SEA), 2019","volume":"31","author":"Ascaso","year":"2019","journal-title":"Clin Investig Arterioscler."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321001246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321001246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:40:53Z","timestamp":1761108053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359321001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1138359321001246"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2021.03.008","relation":{},"ISSN":["1138-3593"],"issn-type":[{"type":"print","value":"1138-3593"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad y seguridad del tratamiento con iPCSK9 en vida real: experiencia de tres hospitales asturianos","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}